Efficacy and Safety of Tislelizumab Plus Lenvatinib as First-Line Treatment in Patients with Unresectable Hepatocellular Carcinoma . Medical Forum Monthly, [S. l.], v. 35, n. 6, 2024. Disponível em: https://medicalforummonthly.com/index.php/mfm/article/view/4698.. Acesso em: 1 feb. 2026.